###begin article-title 0
###xml 95 100 <span type="species:ncbi:9606">women</span>
Sex steroid metabolism polymorphisms and mammographic density in pre- and early perimenopausal women
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 252 257 <span type="species:ncbi:9606">women</span>
We examined the association between mammographic density and single-nucleotide polymorphisms (SNPs) in genes encoding CYP1A1, CYP1B1, aromatase, 17beta-HSD, ESR1, and ESR2 in pre- and early perimenopausal white, African-American, Chinese, and Japanese women.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 13 18 <span type="species:ncbi:9606">Women</span>
###xml 150 162 <span type="species:ncbi:9606">participants</span>
The Study of Women's Health Across the Nation is a longitudinal community-based cohort study. We analyzed data from 451 pre- and early perimenopausal participants of the ancillary SWAN Mammographic Density study for whom we had complete information regarding mammographic density, genotypes, and covariates. With multivariate linear regression, we examined the relation between percentage mammographic breast density (outcome) and each SNP (primary predictor), adjusting for age, race/ethnicity, parity, cigarette smoking, and body mass index (BMI).
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 35 42 35 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1B1 </italic>
###xml 143 145 143 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 158 166 158 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP19A1 </italic>
###xml 264 266 264 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 308 315 308 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 </italic>
###xml 425 427 425 427 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 470 472 470 472 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 474 486 474 486 <sub xmlns:xlink="http://www.w3.org/1999/xlink">interaction </sub>
###xml 525 530 525 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 632 634 632 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 383 395 <span type="species:ncbi:9606">participants</span>
###xml 507 519 <span type="species:ncbi:9606">participants</span>
After multivariate adjustment, the CYP1B1 rs162555 CC genotype was associated with a 9.4% higher mammographic density than the TC/TT genotype (P = 0.04). The CYP19A1 rs936306 TT genotype was associated with 6.2% lower mammographic density than the TC/CC genotype (P = 0.02). The positive association between CYP1A1 rs2606345 and mammographic density was significantly stronger among participants with BMI greater than 30 kg/m2 than among those with BMI less than 25 kg/m2 (Pinteraction = 0.05). Among white participants, the ESR1 rs2234693 CC genotype was associated with a 7.0% higher mammographic density than the CT/TT genotype (P = 0.01).
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
SNPs in certain genes encoding sex steroid metabolism enzymes and ESRs were associated with mammographic density. Because the encoded enzymes and ESR1 are expressed in breast tissue, these SNPs may influence breast cancer risk by altering mammographic density.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 138 139 138 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 264 265 264 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 433 434 433 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 671 672 671 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 673 674 673 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
High mammographic breast density, the density of the breast on mammography, is one of the strongest known risk factors for breast cancer [1]. High breast density (dense tissue on 50% or more of the breast) could account for up to one third of breast cancer cases [2]. Factors such as body mass index, parity, age, smoking, and physical activity jointly account for only a small proportion of the variability in mammographic density [3]. In contrast, mammographic density has a strong genetic component. Twin studies have demonstrated that heritability (the proportion of variance attributable to genetic factors) accounts for 60% of the variance in mammographic density [4,5].
###end p 11
###begin p 12
###xml 328 329 328 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 494 496 494 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 755 757 746 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 758 760 749 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 995 996 986 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 997 999 988 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1000 1002 991 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1121 1123 1112 1114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1124 1126 1115 1117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1127 1129 1118 1120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1130 1132 1121 1123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1135 1143 1126 1134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP19A1 </italic>
###xml 1260 1261 1251 1252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1262 1264 1253 1255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1357 1359 1345 1347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1503 1505 1491 1493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1709 1710 1697 1698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
It is feasible that genetic variation in sex steroids or in estrogen receptors (ESRs) produced in breast tissue could lead to differing degrees of proliferation that may be manifest radiographically as interindividual differences in mammographic density. The presence of sex steroid metabolic enzymes and ESRs in breast tissue [6-24] suggests that local activation of estrogen to potentially reactive metabolites within breast tissue may play a role in initiating and promoting carcinogenesis [18]. Such enzymes include CYP1A1, CYP1B1, and 17beta-hydroxysteroid dehydrogenase (17beta-HSD). In addition to metabolizing environmental carcinogens (for example, polycyclic aromatic hydrocarbons), CYP1A1 has high activity with the 17beta-estradiol substrate [25,26]. CYP1A1 forms mainly 2-hydroxyestrone, and to a lesser degree, some 4-hydroxyestrone, from estrone. In contrast, CYP1B1 predominantly catalyzes formation of potentially carcinogenic catechol estrogens, especially 4-hydroxyestrogens [6,26-28]. The implication of 4-hydroxy catechol estrogens in carcinogenesis suggests a key role for CYP1B1 in carcinogenesis [19,27,29,30]. CYP19A1 is the gene encoding the aromatase enzyme that catalyzes the formation of aromatic C18 estrogens from C19 androgens [6,31]. Type I 17beta-HSD is the enzyme responsible for interconversion of estrone and estradiol [32]. In addition to potential local effects of these enzymes on breast tissue, ESR-estrogen interactions stimulate breast epithelial cell growth [33]. Single-nucleotide polymorphisms (SNPs) in genes encoding sex steroid-metabolizing enzymes or receptors have effects on the hormonal milieu of the breast and on levels of potential mammary carcinogens [6].
###end p 12
###begin p 13
###xml 152 154 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 155 157 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 220 222 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 223 225 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 318 320 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 412 413 409 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 213 218 <span type="species:ncbi:9606">women</span>
###xml 678 683 <span type="species:ncbi:9606">women</span>
A few studies have explored associations between mammographic density and SNPs in genes encoding CYP1A1, CYP1B1, aromatase, 17beta-HSD, ESR1, and ESR2 [34-39]. However, most studies were focused on postmenopausal women [36,37]. Premenopausal breast density may be more highly heritable than is postmenopausal density [40], and some genes may be associated with premenopausal but not with postmenopausal density [4]. The goal of this study was to examine the association between mammographic density and SNPs in genes encoding CYP1A1, CYP1B1, aromatase, type I 17beta-HSD, ESR1, and ESR2 in a group of pre- and early perimenopausal white, African-American, Chinese, and Japanese women.
###end p 13
###begin title 14
Materials and methods
###end title 14
###begin p 15
###xml 146 151 <span type="species:ncbi:9606">women</span>
###xml 352 357 <span type="species:ncbi:9606">women</span>
To determine the association between SNPs in genes encoding sex steroid-metabolizing enzymes and ESRs and mammographic density, we used data from women who participated in the SWAN ancillary Mammographic Density Study and the SWAN Genetics Study, which are described later. All protocols were IRB approved at participating sites, and all participating women provided signed, written informed consent.
###end p 15
###begin title 16
###xml 13 18 <span type="species:ncbi:9606">Women</span>
The Study of Women's Health Across the Nation (SWAN)
###end title 16
###begin p 17
###xml 528 530 528 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 79 84 <span type="species:ncbi:9606">women</span>
###xml 183 188 <span type="species:ncbi:9606">women</span>
###xml 697 702 <span type="species:ncbi:9606">women</span>
###xml 718 723 <span type="species:ncbi:9606">women</span>
###xml 791 796 <span type="species:ncbi:9606">women</span>
###xml 855 860 <span type="species:ncbi:9606">women</span>
###xml 885 890 <span type="species:ncbi:9606">women</span>
###xml 917 922 <span type="species:ncbi:9606">women</span>
###xml 951 963 <span type="species:ncbi:9606">participants</span>
SWAN is a multisite longitudinal community-based cohort study of 3,302 midlife women, serving as the parent study for the Mammographic Density ancillary study. In brief, at baseline, women were aged 42 to 52 years and premenopausal (reporting no change in usual menstrual pattern) or early perimenopausal (reporting change in menstrual pattern but occurrence of menstruation in the past 3 months), had an intact uterus and one or more ovaries, were not pregnant or lactating, and were not using exogenous reproductive hormones [41]. Initiation of exogenous hormones after the baseline visit did not preclude inclusion in the longitudinal cohort study. Each of the seven study sites enrolled white women in addition to women of one other self-identified racial/ethnic group: African-American women (Boston, Detroit area, Chicago, and Pittsburgh), Japanese women (Los Angeles), Hispanic women (New Jersey), and Chinese women (Oakland, California). SWAN participants completed questionnaires and underwent fasting blood sampling annually.
###end p 17
###begin title 18
The SWAN Mammographic Density Study
###end title 18
###begin p 19
###xml 162 174 <span type="species:ncbi:9606">participants</span>
Three SWAN clinical sites (Los Angeles, Oakland, Pittsburgh) participated in the SWAN Mammographic Density ancillary study, which retrieved and analyzed existing participants' mammograms that had been performed by accredited mammography facilities as a part of routine medical care.
###end p 19
###begin p 20
###xml 58 70 <span type="species:ncbi:9606">participants</span>
###xml 121 126 <span type="species:ncbi:9606">women</span>
###xml 305 310 <span type="species:ncbi:9606">women</span>
###xml 402 407 <span type="species:ncbi:9606">women</span>
At the time of enrollment into the ancillary study, 1,248 participants were active at the three sites. Of these, 22 (2%) women were ineligible because of bilateral breast surgery, 82 (7%) were not recruited because of having an abbreviated follow-up, and 89 (7%) refused to participate. Thus, 1,055 (85%) women were eligible and agreed to participate in the mammographic density study; of these, 1,005 women had at least one mammographic density assessment.
###end p 20
###begin p 21
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 858 860 858 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 287 298 <span type="species:ncbi:9606">participant</span>
By using previously published methods, a single expert reviewer quantified mammographic density (that is, the percentage of the breast composed of dense tissue) [42]. The reader assessed mammographic density by using the craniocaudal view of the mammogram of the right breast [43]. If a participant reported prior breast surgery involving the right breast, mammograms of the left breast were used for density assessments. A compensating polar planimeter was used to measure the total breast area (in square centimeters) and the area of dense breast tissue (in square centimeters). Percentage density was calculated as the area of dense breast tissue divided by the area of the breast. A repeated review of a 10% random subset of mammograms for intrarater reliability yielded an intraclass correlation coefficient for percentage mammographic density of 0.96 [43].
###end p 21
###begin p 22
###xml 107 119 <span type="species:ncbi:9606">participants</span>
###xml 134 146 <span type="species:ncbi:9606">participants</span>
###xml 305 317 <span type="species:ncbi:9606">participants</span>
###xml 370 381 <span type="species:ncbi:9606">participant</span>
###xml 588 599 <span type="species:ncbi:9606">participant</span>
###xml 781 792 <span type="species:ncbi:9606">participant</span>
Our goal was to examine associations of SNPs with mammographic density among pre- and early perimenopausal participants. Of the 1,005 participants with at least one assessment of mammographic density, we chose one mammogram for each of the 643 pre- or early perimenopausal SWAN Mammographic Density study participants. If more than one mammogram was available for given participant, we selected the mammogram temporally closest to the preceding annual follow-up visit that was flanked by pre- or early perimenopausal status on the visits before and after the mammogram. For example, if a participant had mammographic density assessments from two mammograms during her premenopausal stage and one mammogram during her early perimenopausal stage, we chose a single mammogram for the participant by picking the mammogram that was temporally closest to its preceding annual follow-up visit. Mammograms that occurred more than 3 months before baseline and mammograms obtained during the use of current exogenous reproductive hormones were excluded.
###end p 22
###begin title 23
The SWAN Genetics Study
###end title 23
###begin p 24
###xml 108 109 108 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 117 118 117 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 416 418 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 134 139 <span type="species:ncbi:9606">women</span>
The SWAN Genetics Study genotyped 25 SNPs relating to sex-steroid metabolism and estrogen receptors (Figure 1, Table 1). Of the 1,988 women who were eligible (that is, still participating and providing blood for the SWAN parent study at the follow-up year 5 visit), 88% agreed to participate in the genetics study. Details regarding specimen collection, specimen processing, and genotyping were previously reported [44]. Genotyping was performed by using TaqMan (Roche Molecular Systems, Inc., Pleasanton, CA) and an ABI 7900 HT sequence detection system (Applied Biosystems Inc., Foster City, CA, USA).
###end p 24
###begin p 25
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B93">93</xref>
Functions of SWAN genetics sex steroid metabolism enzymes and receptors. Used with permission of Sowers and colleagues [93].
###end p 25
###begin p 26
SNPs examined in the SWAN Genetics Study
###end p 26
###begin p 27
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 54 55 54 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 84 85 84 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 126 127 126 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 164 165 164 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink">e</sup>
aReference (higher frequency) allele is listed first. bEncodes Coenzyme A synthase. cEncodes lectin, mannose-binding, 1-like. dEncodes LOC732 hypothetical protein. eEncodes gliomedine.
###end p 27
###begin p 28
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 534 536 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 537 539 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 577 579 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 580 582 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 601 603 601 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 635 637 635 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
Between three and eight SNPs per gene were selected based on use in previous genetics studies, a review of the literature, and information from gene databases (National Center for Biotechnology SNP database [45] and Celera [46]). The original SNP selection process is discussed in the first SWAN Genetics Study manuscript [44]. The SWAN Genetics Study searched for published literature supporting the biologic significance of SNPs chosen. SNPs were chosen if they were thought potentially to influence circulating sex hormone levels [47,48] or disease patterns: breast cancer [49-51], ovarian cancer [52], and bone mineral density [53,54].
###end p 28
###begin p 29
###xml 54 66 <span type="species:ncbi:9606">participants</span>
###xml 178 183 <span type="species:ncbi:9606">women</span>
###xml 220 231 <span type="species:ncbi:9606">participant</span>
###xml 299 311 <span type="species:ncbi:9606">participants</span>
###xml 458 463 <span type="species:ncbi:9606">women</span>
Of the 643 premenopausal or early perimenopausal SWAN participants with available mammographic density information, at least partial genotyping data were available for 463 (72%) women. For this analysis, we excluded one participant lacking genotyping data for 24 of the 25 SNPs and an additional 11 participants who were missing information for one or more covariates. Thus, the analytic sample for this study comprised the 451 pre- and early perimenopausal women for whom complete information was available regarding mammographic density, genotypes, and covariates.
###end p 29
###begin title 30
Questionnaire-based and anthropometric measures
###end title 30
###begin p 31
###xml 53 65 <span type="species:ncbi:9606">participants</span>
At baseline and at each annual follow-up visit, SWAN participants were asked to complete standardized questionnaires and underwent measurement of height and weight for calculation of body mass index (BMI, weight in kilograms divided by the square of the height in meters). We took information regarding age, race/ethnicity, reproductive history, medication use, smoking, and alcohol intake from annual questionnaires.
###end p 31
###begin title 32
Statistical analysis
###end title 32
###begin p 33
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 183 185 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 257 259 257 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Allele frequencies in the SWAN Genetics Study were estimated by race/ethnicity (Mendel Version 8.0 [55]). Hardy-Weinberg equilibrium (HWE) was assessed by using Fisher's Exact tests [55]. Because of the multiple statistical tests performed, we considered a P value of < 0.01 as the criterion to reject the null hypothesis of HWE.
###end p 33
###begin p 34
###xml 426 427 426 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 428 430 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 924 926 924 926 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 861 873 <span type="species:ncbi:9606">participants</span>
Creating a separate model for each of the 25 SNPs, we used multivariate linear regression to examine the relation between percentage mammographic breast density (outcome) and SNP (primary predictor). Based on previously published studies, we considered the following candidate covariates: age, race/ethnicity, number of live births, BMI, oral contraceptive use, menopausal hormone use, cigarette smoking, and alcohol intake) [3,43,56-68]. Of these candidate covariates, age, number of live births, and BMI were included in all models, based on previously well-established associations with mammographic density. The remaining candidate covariates (cigarette smoking, alcohol intake, oral contraceptive use, and menopausal hormone use) were evaluated for model inclusion by using backwards regression performed on data from the 643 pre- and early perimenopausal participants of the SWAN Mammographic Density study. We used a P value of 0.10 as the cutoff for covariate inclusion. In addition, because each site recruited a specific racial/ethnic group in addition to non-Hispanic whites, a combined variable was created for race/ethnicity and study site; this variable was included in all models. Categories for this variable were whites in Oakland, Chinese in Oakland, whites in Los Angeles, Japanese in Los Angeles, white in Pittsburgh, or African American in Pittsburgh. Age at mammogram (continuous), race/ethnicity-study site, number of live births (continuous), current cigarette smoking (yes/no), and BMI (continuous) were the covariates retained in the final models. We modeled the alleles as acting in either an additive (aa versus Aa and AA, where the effect of the Aa genotype is half the effect of the AA genotype) or recessive (aa/Aa versus AA) manner, in which A is the minor allele.
###end p 34
###begin p 35
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 709 711 709 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 105 110 <span type="species:ncbi:9606">women</span>
###xml 591 603 <span type="species:ncbi:9606">participants</span>
Because of prior studies showing that associations of sex steroid-related SNPs may be more evident among women with BMI greater than 25 [69], we conducted secondary analyses wherein we added an SNP*BMI interaction term to the multivariable linear regression models. Because we suspected that the sample size of certain racial/ethnic subgroups may have been too small to allow detection of SNP*race/ethnicity interactions, and because the allele frequencies for 13 of the 25 SNPs differed by more than 0.20 between the ethnic groups, we repeated all of our analyses in the subsample of white participants, the largest racial/ethnic subgroup. All regression analyses were performed with the software program R [70].
###end p 35
###begin title 36
Results
###end title 36
###begin title 37
###xml 32 44 <span type="species:ncbi:9606">participants</span>
Baseline characteristics of the participants
###end title 37
###begin p 38
###xml 139 140 139 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 358 359 358 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 386 387 386 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 705 706 705 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 300 312 <span type="species:ncbi:9606">participants</span>
###xml 463 475 <span type="species:ncbi:9606">participants</span>
Baseline characteristics of the analytic sample (N = 451 with mammographic density, genotyping, and covariate data) are displayed in Table 2. No notable differences in characteristics were found between the overall mammographic density sample (N = 643) and the analytic sample. The median age of the participants in the analytic sample was 48.7 years (Table 2). Median BMI was 24.4 kg/m2. Mean percentage mammographic density was 43.6%. Forty-nine percent of the participants in the analytic sample were white, 24% were Chinese, 22% were Japanese, and 6% were African American. Twenty-six percent were premenopausal, and 74% were early perimenopausal at the visit immediately preceding mammography (Table 2).
###end p 38
###begin p 39
###xml 29 41 <span type="species:ncbi:9606">participants</span>
Characteristics of the study participants: analytic sample of the current study (N = 451)
###end p 39
###begin p 40
###xml 57 68 <span type="species:ncbi:9606">participant</span>
###xml 110 121 <span type="species:ncbi:9606">participant</span>
Baseline menopause stage information was missing for one participant whose baseline mammogram was chosen; the participant was early perimenopausal at the subsequent (first annual) visit.
###end p 40
###begin title 41
Hardy-Weinberg Equilibrium assessment
###end title 41
###begin p 42
###xml 51 52 51 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 82 83 82 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 123 133 123 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP194947 </italic>
We examined allele frequencies by ethnicity (Table 3) and assessed HWE (see Table 4). Within racial/ethnic subgroups, only CYP194947 showed significant deviation from HWE. Because this SNP was also the SNP with the highest frequency (8%) of missing genotypes, methodologic considerations related to genotyping of this SNP may have contributed to deviation from HWE.
###end p 42
###begin p 43
###xml 42 54 <span type="species:ncbi:9606">participants</span>
Allele frequencies of SWAN Genetics Study participants by race/ethnicity
###end p 43
###begin p 44
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aNo corresponding dbsnp rs number; commonly referred to as CYP194947.
###end p 44
###begin p 45
Hardy-Weinberg equilibrium evaluation by race/ethnicity
###end p 45
###begin p 46
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aNo corresponding dbsnp rs number; commonly referred to as CYP194947.
###end p 46
###begin title 47
Associations between SNPs and percentage mammographic density
###end title 47
###begin p 48
###xml 184 185 184 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 190 191 190 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T6">6</xref>
We examined the association between percentage mammographic breast density and each of the SNPs in models adjusted for age, race/ethnicity-study site, parity, smoking, and BMI (Tables 5 and 6).
###end p 48
###begin p 49
###xml 97 98 97 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
Percentage mammographic density as a function of single-nucleotide polymorphism: recessive modelsa
###end p 49
###begin p 50
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aReference allele was the allele with the higher frequency in the overall analytic sample and is indicated in the first column for each SNP.
###end p 50
###begin p 51
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
bBecause each site recruited a specific racial/ethnic group in addition to non-Hispanic whites, a combined variable was created for race/ethnicity and study site.
###end p 51
###begin p 52
###xml 96 97 96 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
Percentage mammographic density as a function of single-nucleotide polymorphism: additive modelsa
###end p 52
###begin p 53
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 141 142 141 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 304 305 304 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
aReference allele was the allele with the higher frequency in the overall analytic sample and is indicated in the first column for each SNP. bBecause each site recruited a specific racial/ethnic group in addition to non-Hispanic whites, a combined variable was created for race/ethnicity and study site. cNo corresponding dbsnp rs number; commonly referred to as CYP194947.
###end p 53
###begin p 54
###xml 116 123 116 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1B1 </italic>
###xml 233 235 233 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 248 256 248 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP19A1 </italic>
###xml 361 363 361 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 378 379 378 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 440 445 440 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 602 603 602 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 608 609 608 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T6">6</xref>
###xml 426 438 <span type="species:ncbi:9606">participants</span>
In the fully adjusted recessive models (adjusted for age, race/ethnicity-study site, parity, smoking, and BMI), the CYP1B1 rs162555 CC genotype was associated with 9.4% higher percentage mammographic density than the TC/TT genotype (P = 0.04). The CYP19A1 rs936306 TT genotype was associated with 6.2% lower percentage mammographic density than TC/CC genotype (P = 0.03) (Table 5). In contrast to analyses restricted to white participants, ESR1 rs2234693 was not significantly associated with mammographic density in either recessive or additive models that included the entire analytic sample (Tables 5 and 6).
###end p 54
###begin title 55
Interaction by BMI
###end title 55
###begin p 56
###xml 20 27 20 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 </italic>
###xml 84 86 84 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 112 114 112 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 126 134 126 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP19A1 </italic>
###xml 153 155 153 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 180 182 180 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 276 286 276 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP194947 </italic>
###xml 328 330 328 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 374 376 374 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 393 401 393 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP19A1 </italic>
###xml 452 454 452 454 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 489 491 489 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 258 270 <span type="species:ncbi:9606">participants</span>
In additive models, CYP1A1 rs2606345 was significantly associated with BMI (1.1 kg/m2 higher for each A allele; P = 0.03) and CYP19A1 rs2414096 (1.1 kg/m2 lower for each A allele; P = 0.01; data not shown). Similarly, in recessive models restricted to white participants, the CYP194947 GG genotype was associated with a 2.1 kg/m2 lower BMI compared with the GA/AA genotype (P = 0.05), and the CYP19A1 rs749292 AA genotype was associated with a 2.3 kg/m2 lower BMI than the GA/GG genotype (P = 0.05; data not shown).
###end p 56
###begin p 57
###xml 347 354 347 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 </italic>
###xml 485 487 485 487 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 541 543 541 543 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 545 557 545 557 <sub xmlns:xlink="http://www.w3.org/1999/xlink">interaction </sub>
###xml 626 627 626 627 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 687 694 687 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 </italic>
###xml 776 777 776 777 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 957 965 957 965 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP19A1 </italic>
###xml 976 984 976 984 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP19A1 </italic>
###xml 997 1006 997 1006 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP194947</italic>
###xml 442 454 <span type="species:ncbi:9606">participants</span>
###xml 501 513 <span type="species:ncbi:9606">participants</span>
###xml 586 598 <span type="species:ncbi:9606">participants</span>
###xml 733 745 <span type="species:ncbi:9606">participants</span>
To determine whether associations between SNPs and mammographic density varied according to BMI, we added BMI*SNP interaction terms to multiple linear regression models that included age, race/ethnicity-study site, smoking, parity, and BMI as covariates and percentage mammographic density as the outcome (data not shown). In additive models, the CYP1A1 rs2606345-mammographic density association was significantly different (stronger) among participants with BMIs greater than 30 kg/m2 compared with participants with BMIs less than 25 kg/m2 (Pinteraction = 0.05). Specifically, among participants with BMIs less than 25 kg/m2, percentage mammographic density was 0.57% higher for each CYP1A1 rs2606345 C allele; in contrast, among participants with BMIs greater than 30 kg/m2, percentage mammographic density was 6.1% higher for each additional C allele. The associations of SNPs with mammographic density did not significantly differ by BMI category for CYP19A1 rs2414096, CYP19A1 rs749292, or CYP194947. However, we may not have had adequate statistical power to detect an SNP*BMI interaction when BMI was categorized into tertiles.
###end p 57
###begin title 58
###xml 29 41 <span type="species:ncbi:9606">participants</span>
Analyses restricted to white participants
###end title 58
###begin p 59
###xml 150 167 150 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP19A1 rs936306 </italic>
###xml 188 196 188 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP19A1 </italic>
###xml 254 259 254 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 372 374 372 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 388 389 388 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 443 445 443 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 459 460 459 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T6">6</xref>
###xml 487 492 487 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 623 625 623 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 662 664 662 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 236 248 <span type="species:ncbi:9606">participants</span>
###xml 677 689 <span type="species:ncbi:9606">participants</span>
In analyses restricted to whites (n = 219), we detected two associations that were similar to those seen in the overall analytic sample (for example, CYP19A1 rs936306 in recessive models, CYP19A1 rs2414096 in additive models). In white participants, the ESR1 rs2234693 CC genotype was associated with a 7.0% higher percentage mammographic density than the CT/TT genotype (P = 0.01; Table 5); this finding was also apparent in additive models (P = 0.01; Table 6). The association between ESR1 rs2234693 and mammographic density varied by ethnicity; the association was stronger among whites than among Japanese (interaction P value, 0.09) or Chinese (interaction P value, 0.03) participants.
###end p 59
###begin title 60
Discussion
###end title 60
###begin p 61
###xml 55 62 55 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1B1 </italic>
###xml 86 94 86 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP19A1 </italic>
###xml 125 130 125 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 262 269 262 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 </italic>
###xml 280 289 280 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP194947</italic>
###xml 291 299 291 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP19A1 </italic>
###xml 309 317 309 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP19A1 </italic>
###xml 725 726 725 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 33 38 <span type="species:ncbi:9606">women</span>
In pre- and early perimenopausal women, SNPs involving CYP1B1 (rs162555 CC genotype), CYP19A1 (rs936306 TT/CC genotype), and ESR1 (rs2234693 CC genotype) were each significantly positively associated with mammographic density. Associations between several SNPs (CYP1A1 rs2606345, CYP194947, CYP19A1 rs749292, CYP19A1 rs2414096) and mammographic density were attenuated after adjustment for BMI. Percentage mammographic density varied at least 3% per allele for the statistically significant associations. These differences in mammographic density according to genotype are of a clinically relevant magnitude, given that each 1% increment in mammographic density is associated with a 2% higher relative risk of breast cancer [2]. Several SNP-mammographic density associations varied significantly by ethnicity.
###end p 61
###begin p 62
###xml 179 190 179 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">17&#946;-HSD </italic>
###xml 200 211 197 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">17&#946;-HSD </italic>
###xml 221 232 215 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">17&#946;-HSD </italic>
###xml 240 245 231 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 255 260 246 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 271 276 262 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 </italic>
###xml 287 292 278 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 </italic>
###xml 303 308 294 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 </italic>
###xml 319 326 310 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1B1 </italic>
###xml 336 343 327 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1B1 </italic>
###xml 354 362 345 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP19A1 </italic>
###xml 372 380 363 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP19A1 </italic>
###xml 391 399 382 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP19A1 </italic>
###xml 410 418 401 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP19A1 </italic>
###xml 429 437 420 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP19A1 </italic>
###xml 447 455 438 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP19A1 </italic>
###xml 466 474 457 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP19A1 </italic>
###xml 484 493 475 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP194947</italic>
###xml 495 502 486 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 </italic>
###xml 516 523 507 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 </italic>
Several of our findings are novel. As far as we know, other publications have not reported information regarding associations between mammographic density and the following SNPs: 17beta-HSD rs615942, 17beta-HSD rs592389, 17beta-HSD rs2830, ESR1 rs728524, ESR1 rs3798577, ESR2 rs1256030, ESR2 rs1255998, ESR2 rs1256049, CYP1B1 rs162555, CYP1B1 rs1800440, CYP19A1 rs700519, CYP19A1 rs2446405, CYP19A1 rs2445759, CYP19A1 rs1008805, CYP19A1 rs936306, CYP19A1 rs2414096, CYP19A1 rs749292, CYP194947, CYP1A1 rs1531163, or CYP1A1 rs2606345.
###end p 62
###begin p 63
###xml 38 43 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 155 160 155 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 335 337 335 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 90 95 <span type="species:ncbi:9606">women</span>
Our finding of an association between ESR1 rs2234693 and mammographic density among white women conflicts with some prior studies. The association between ESR1 rs2234693 and mammographic density was described in three reports from the EPIC study. In the first EPIC report, the T allele was associated with higher mammographic density [39], whereas in this study, the CC genotype is associated with higher mammographic density.
###end p 63
###begin p 64
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B71">71</xref>
###xml 165 170 <span type="species:ncbi:9606">women</span>
The second EPIC analysis found a statistically significant difference in mammographic density between hormone therapy users and never-users of hormone therapy among women the CT or TT genotype, but not among those with the CC genotype [71].
###end p 64
###begin p 65
###xml 56 61 56 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 299 304 <span type="species:ncbi:9606">women</span>
The third EPIC analysis reported no association between ESR1 rs2234693 and mammographic density [36]; the discrepancy among studies may be because the previous study used a different mammographic density measurement technique, had a less heterogenous study population, and focused on postmenopausal women.
###end p 65
###begin p 66
###xml 32 39 32 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1B1 </italic>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
We found an association between CYP1B1 rs1056836 and mammographic density that neared statistical significance only before adjustment, but not after adjustment, for BMI. These results may be consistent with three previously published studies [35,36,38].
###end p 66
###begin p 67
###xml 152 157 152 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 56 61 <span type="species:ncbi:9606">women</span>
###xml 306 318 <span type="species:ncbi:9606">participants</span>
###xml 358 370 <span type="species:ncbi:9606">participants</span>
A cross-sectional observational European study of white women found statistically significantly higher mammographic density in carriers of at least one ESR1 rs9340799 A allele [39]. Although we had similar results, our findings were not statistically significant, possibly because of the smaller number of participants in our study or the younger age of our participants.
###end p 67
###begin p 68
###xml 254 261 254 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 </italic>
###xml 275 282 275 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 </italic>
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 296 298 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
The other SNPs involved in sex steroid metabolism or estrogen receptors were not significantly associated with mammographic density in the present study. As with our study, past studies reported absence of an association between mammographic density and CYP1A1 rs1048943 and CYP1A1 rs4646903 [35,38].
###end p 68
###begin p 69
###xml 535 536 535 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 536 538 536 538 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 549 556 549 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1A1 </italic>
###xml 772 780 772 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP19A1 </italic>
###xml 937 938 937 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 938 940 938 940 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 1040 1047 1040 1047 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1B1 </italic>
###xml 1210 1217 1210 1217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1B1 </italic>
Although previously published studies have not included a systematic examination of sex steroid metabolism SNPs and mammographic density, some previously studied SNPs may be linked with the SNPs that we examined. We searched Haploview version 4.1 (Daly Lab, Cambridge, MA) with Hapmap genotype data to search for information regarding linkage disequilibrium for each of the three SNPs that we found to be associated with mammographic density and other SNPs previously studied in relation to mammographic density. Linkage diseqilibrium R2 values for ESR1A1 rs2234693 (which we found to be associated with mammographic density) and rs9340799 (which prior studies found to be associated with mammographic density) range from 0.234 to 0.55, depending on the ethnic group. For CYP19A1 rs936306 (which we found to be associated with mammographic density) and rs10046 (which prior studies found not to be associated with mammographic density), R2 values range from 0.017 to 0.193. Linkage-disequilibrium information is not currently available for CYP1B1 rs162555 on Hapmap. Although LD information was not available for rs162555, we note that its chromosomal location is not close to the other two previously studied CYP1B1 SNPs.
###end p 69
###begin p 70
###xml 164 169 164 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B74">74</xref>
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B75">75</xref>
###xml 376 378 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B76">76</xref>
###xml 391 399 391 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP19A1 </italic>
###xml 468 470 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B77">77</xref>
###xml 527 532 527 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 543 545 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 546 548 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B76">76</xref>
###xml 549 551 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B78">78</xref>
###xml 552 554 552 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B87">87</xref>
###xml 575 583 575 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP19A1 </italic>
###xml 593 595 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B77">77</xref>
###xml 596 598 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B88">88</xref>
###xml 883 890 883 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 </italic>
###xml 1158 1165 1158 1165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 </italic>
###xml 1264 1269 1264 1269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 1366 1368 1366 1368 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 1369 1371 1369 1371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 744 756 <span type="species:ncbi:9606">participants</span>
###xml 1086 1091 <span type="species:ncbi:9606">women</span>
###xml 1331 1336 <span type="species:ncbi:9606">women</span>
Our findings have a biologic rationale. A local influence of sex steroid metabolism SNPs on breast tissue is suggested by prior breast cancer studies. For example, ESR1 rs2234693 has been associated with duration of breast cancer survival [72], degree of breast cancer differentiation [73], age at breast cancer diagnosis [74], and receptor status of breast cancer tumors [75,76]. Likewise, CYP19A1 rs936306 may be associated with breast cancer disease-free survival [77]. Case-control studies of breast cancer risk related to ESR1 rs2234693 [73,76,78-87] and in relation to CYP19A1 rs936306 [77,88] are conflicting. Inconsistent results of breast cancer case-control studies are likely due to differences in ethnicity and menopausal status of participants across studies. Reasons exist to suspect that associations of SNPs with mammographic density may vary by BMI, as we found for CYP1A1 rs2606345. Sex steroid metabolism (for example, peripheral aromatization of androstenedione) varies by BMI, so that effects of sex steroid SNPs on breast tissue may be more pronounced among obese women. Although prior studies have not examined whether associations of CYP1A1 rs2606345 with mammographic density vary by BMI, a prior study reported that the association of an ESR1 SNP with increased breast cancer risk was apparent only among women with BMI greater than 25 kg/m2 [69].
###end p 70
###begin p 71
###xml 908 910 908 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B89">89</xref>
###xml 911 913 911 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B91">91</xref>
###xml 1073 1075 1073 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B92">92</xref>
Strengths of our study included its multiethnic study population, use of validated and reproducible mammographic density-assessment techniques, rigorous attention to genotyping methods, and collection of detailed information regarding key covariates related to mammographic density. However, this study did not directly assess sex steroid activity in breast tissue samples. Furthermore, although our sample size was relatively large, its heterogeneity may have precluded detection of statistically significant race-specific associations or interactions of SNPs with mammographic density. Finally, the observational study design precluded coordination of mammographic density with menstrual-cycle phase. Relations between SNPs and mammographic density may have been diluted because we analyzed mammograms taken during varying menstrual phases. Breasts are more radiographically dense during the luteal phase [89-91], although a recent study found that variation in mammographic density over the menstrual cycle may be subtle (that is, may not be statistically significant) [92].
###end p 71
###begin title 72
Conclusions
###end title 72
###begin p 73
###xml 147 152 <span type="species:ncbi:9606">women</span>
In conclusion, SNPs involving sex steroid metabolism enzymes and ESR1 may be associated with mammographic density in pre- and early perimenopausal women. Future studies relating these SNPs to mammographic density not only should adjust for BMI but also should consider interactions by BMI. The mechanisms underlying the association (for example, increased proliferation of epithelial and stromal cells) require elucidation. Because these enzymes and ESR1 are expressed in target tissues, these SNPs (or genetic factors with which they are in linkage disequilibrium) may alter breast cancer risk by altering mammographic density. These findings inform the understanding of biologic influences on mammographic density, a strong risk factor for breast cancer.
###end p 73
###begin title 74
Abbreviations
###end title 74
###begin p 75
###xml 188 193 <span type="species:ncbi:9606">Women</span>
BMI: body mass index; CYP: cytochrome P450; ESR: estrogen receptor; HSD: hydroxysteroid dehydrogenase; HWE: Hardy Weinberg equilibrium; SNP: single-nucleotide polymorphism; SWAN: Study of Women's Health Across the Nation.
###end p 75
###begin title 76
Competing interests
###end title 76
###begin p 77
The authors declare that they have no competing interests.
###end p 77
###begin title 78
Authors' contributions
###end title 78
###begin p 79
CC contributed to study conception, study design, analysis and interpretation of data, manuscript drafting, and revision. JS and MS contributed to study design. MS, SC, EG, LH, LB, MS, GG, and JS contributed to analysis and interpretation of data and manuscript revision.
###end p 79
###begin title 80
Acknowledgements
###end title 80
###begin p 81
###xml 13 18 <span type="species:ncbi:9606">Women</span>
###xml 255 260 <span type="species:ncbi:9606">Women</span>
###xml 719 724 <span type="species:ncbi:9606">Women</span>
###xml 781 786 <span type="species:ncbi:9606">Women</span>
The Study of Women's Health Across the Nation (SWAN) has grant support from the National Institutes of Health (NIH), DHHS, through the National Institute on Aging (NIA), the National Institute of Nursing Research (NINR), and the NIH Office of Research on Women's Health (ORWH) (grants NR004061; AG012505, AG012535, AG012531, AG012539, AG012546, AG012553, AG012554, AG012495, AG017719). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the NIA, NINR, ORWH, or the NIH. Dr. Crandall's work was supported by National Institutes of Health research grant 5K12 AG01004-08 from the National Institute on Aging and by the Michael Parr Fund for Women's Health Research and Education at the Iris Cantor-UCLA Women's Health Center.
###end p 81
###begin p 82
Clinical Centers: University of Michigan, Ann Arbor, MaryFran Sowers, PI; Massachusetts General Hospital, Boston, MA, Robert Neer, PI 1994-1999; Joel Finkelstein, PI 1999 to present; Rush University, Rush University Medical Center, Chicago, IL, Lynda Powell, PI; University of California, Davis/Kaiser, Ellen Gold, PI; University of California, Los Angeles, Gail Greendale, PI; University of Medicine and Dentistry, New Jersey Medical School, Newark, Gerson Weiss, PI 1994 to 2004; Nanette Santoro, PI 2004 to present; and the University of Pittsburgh, Pittsburgh, PA, Karen Matthews, PI.
###end p 82
###begin p 83
NIH Program Office: National Institute on Aging, Bethesda, MD, Marcia Ory 1994 to 2001; Sherry Sherman, 1994 to present; National Institute of Nursing Research, Bethesda, MD, Program Officers.
###end p 83
###begin p 84
Central Laboratory: University of Michigan, Ann Arbor, Daniel McConnell (Central Ligand Assay Satellite Services).
###end p 84
###begin p 85
SWAN Repository: University of Michigan, Ann Arbor, MaryFran Sowers.
###end p 85
###begin p 86
Coordinating Center: New England Research Institutes, Watertown, MA, Sonja McKinlay, PI 1995 to 2001; University of Pittsburgh, Pittsburgh, PA, Kim Sutton-Tyrrell, PI 2001 to present.
###end p 86
###begin p 87
Steering Committee: Chris Gallagher, Chair
###end p 87
###begin p 88
Susan Johnson, Chair
###end p 88
###begin p 89
###xml 50 55 <span type="species:ncbi:9606">women</span>
We thank the study staff at each site and all the women who participated in SWAN.
###end p 89
###begin article-title 90
Quantitative classification of mammographic densities and breast cancer risk: Results from the Canadian National Breast Screening Study
###end article-title 90
###begin article-title 91
Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States)
###end article-title 91
###begin article-title 92
Heritability of mammographic density, a risk factor for breast cancer
###end article-title 92
###begin article-title 93
The relative importance of genetics and environment on mammographic density
###end article-title 93
###begin article-title 94
Molecular epidemiology of sporadic breast cancer: the role of polymorphic genes involved in oestrogen biosynthesis and metabolism
###end article-title 94
###begin article-title 95
###xml 47 52 <span type="species:ncbi:9606">human</span>
Characterization of cytochrome P450 enzymes in human breast tissue from reduction mammoplasties
###end article-title 95
###begin article-title 96
###xml 53 58 <span type="species:ncbi:9606">women</span>
Estrogen-metabolizing enzymes in breast cancers from women over the age of 80 years
###end article-title 96
###begin article-title 97
###xml 61 66 <span type="species:ncbi:9606">human</span>
Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma
###end article-title 97
###begin article-title 98
###xml 67 72 <span type="species:ncbi:9606">human</span>
Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders
###end article-title 98
###begin article-title 99
###xml 122 127 <span type="species:ncbi:9606">human</span>
Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast
###end article-title 99
###begin article-title 100
###xml 71 76 <span type="species:ncbi:9606">women</span>
Association of CYP1A1 polymorphisms with breast cancer in North Indian women
###end article-title 100
###begin article-title 101
Expression of aromatase and 17beta-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer: an immunocytochemical study
###end article-title 101
###begin article-title 102
Expression of cytochrome P450 CYP1B1 in breast cancer
###end article-title 102
###begin article-title 103
###xml 69 74 <span type="species:ncbi:9606">human</span>
Expression of xenobiotic and steroid hormone metabolizing enzymes in human breast carcinomas
###end article-title 103
###begin article-title 104
###xml 95 100 <span type="species:ncbi:9606">women</span>
Relative imbalances in the expression of estrogen-metabolizing enzymes in the breast tissue of women with breast carcinoma
###end article-title 104
###begin article-title 105
###xml 110 118 <span type="species:ncbi:9606">patients</span>
In situ levels of oestrogen producing enzymes and its prognostic significance in postmenopausal breast cancer patients
###end article-title 105
###begin article-title 106
###xml 74 79 <span type="species:ncbi:9606">human</span>
A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis
###end article-title 106
###begin article-title 107
New development in intracrinology of breast carcinoma
###end article-title 107
###begin article-title 108
###xml 47 48 47 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
Expression of cytochrome P450 1B1 and catechol-O-methyltransferase in breast tissue and their associations with breast cancer risk
###end article-title 108
###begin article-title 109
###xml 45 50 <span type="species:ncbi:9606">human</span>
The expression of cytochrome P450 enzymes in human breast tumours and normal breast tissue
###end article-title 109
###begin article-title 110
###xml 34 39 <span type="species:ncbi:9606">human</span>
Expression of cytochromes P450 in human breast tissue and tumors
###end article-title 110
###begin article-title 111
###xml 42 47 <span type="species:ncbi:9606">human</span>
4-Hydroxylation of estrogens as marker of human mammary tumors
###end article-title 111
###begin article-title 112
Estrogen receptor and breast cancer
###end article-title 112
###begin article-title 113
Environment and cancer: who are susceptible?
###end article-title 113
###begin article-title 114
###xml 113 118 <span type="species:ncbi:9606">human</span>
Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms
###end article-title 114
###begin article-title 115
###xml 45 50 <span type="species:ncbi:9606">human</span>
17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1
###end article-title 115
###begin article-title 116
Molecular mechanisms of estrogen carcinogenesis
###end article-title 116
###begin article-title 117
Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity
###end article-title 117
###begin article-title 118
Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1
###end article-title 118
###begin article-title 119
###xml 55 60 <span type="species:ncbi:9606">women</span>
Influences on circulating oestrogens in postmenopausal women: relationship with breast cancer
###end article-title 119
###begin article-title 120
Steroid receptors in breast cancer
###end article-title 120
###begin article-title 121
Genetic determinants of mammographic density
###end article-title 121
###begin article-title 122
Polymorphisms in steroid hormone pathway genes and mammographic density
###end article-title 122
###begin article-title 123
###xml 135 140 <span type="species:ncbi:9606">women</span>
Associations among mammographic density, circulating sex hormones, and polymorphisms in sex hormone metabolism genes in postmenopausal women
###end article-title 123
###begin article-title 124
###xml 108 113 <span type="species:ncbi:9606">women</span>
Polymorphisms in genes involved in estrogen and progesterone metabolism and mammographic density changes in women randomized to postmenopausal hormone therapy: Results from a pilot study
###end article-title 124
###begin article-title 125
###xml 70 75 <span type="species:ncbi:9606">women</span>
An investigation of mammographic density and gene variants in healthy women
###end article-title 125
###begin article-title 126
Polymorphisms in the estrogen receptor alpha gene and mammographic density
###end article-title 126
###begin article-title 127
Mammographic density of the breast
###end article-title 127
###begin article-title 128
###xml 119 124 <span type="species:ncbi:9606">women</span>
Design, survey sampling and recruitment Methods of SWAN: a multi-center, multi-ethnic, community-based cohort study of women and the menopausal transition
###end article-title 128
###begin article-title 129
Mammographic density and breast cancer after ductal carcinoma in situ
###end article-title 129
###begin article-title 130
Mammographic density in a multiethnic cohort
###end article-title 130
###begin article-title 131
###xml 65 70 <span type="species:ncbi:9606">women</span>
###xml 108 113 <span type="species:ncbi:9606">Women</span>
Characterizing variation in sex steroid hormone pathway genes in women of 4 races/ethnicities: the Study of Women's Health Across the Nation (SWAN)
###end article-title 131
###begin article-title 132
National Center for Biotechnology SNP database
###end article-title 132
###begin article-title 133
Celera
###end article-title 133
###begin article-title 134
###xml 128 133 <span type="species:ncbi:9606">women</span>
Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women
###end article-title 134
###begin article-title 135
###xml 86 91 <span type="species:ncbi:9606">women</span>
The CYP19 gene and associations with androgens and abdominal obesity in premenopausal women
###end article-title 135
###begin article-title 136
A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort
###end article-title 136
###begin article-title 137
Estrogen receptor genotypes and haplotypes associated with breast cancer risk
###end article-title 137
###begin article-title 138
Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer
###end article-title 138
###begin article-title 139
CYP1A1 gene polymorphism and risk of epithelial ovarian neoplasm
###end article-title 139
###begin article-title 140
Association of bone mineral density with polymorphism of the estrogen receptor gene
###end article-title 140
###begin article-title 141
###xml 45 50 <span type="species:ncbi:9606">women</span>
Bone mineral density and its change in white women: estrogen and vitamin D receptor genotypes and their interaction
###end article-title 141
###begin article-title 142
Mendel version 4.0: A complete package for the exact genetic analysis of discrete traits in pedigree and population data sets
###end article-title 142
###begin article-title 143
###xml 75 80 <span type="species:ncbi:9606">women</span>
Associations of breast cancer risk factors with breast density in Hispanic women
###end article-title 143
###begin article-title 144
Ethnic differences in mammographic densities
###end article-title 144
###begin article-title 145
Mammographic density and breast cancer risk: the multiethnic cohort study
###end article-title 145
###begin article-title 146
Prior HRT use, ethnicity and mammographic density
###end article-title 146
###begin article-title 147
Are breast density and bone mineral density independent risk factors for breast cancer?
###end article-title 147
###begin article-title 148
Correlates of high-density mammographic parenchymal patterns by menopausal status in a rural population in Northern Greece
###end article-title 148
###begin article-title 149
Different effects of tibolone and continuous combined estrogen plus progestogen hormone therapy on sex hormone binding globulin and free testosterone levels: an association with mammographic density
###end article-title 149
###begin article-title 150
###xml 92 97 <span type="species:ncbi:9606">women</span>
Risk factors for breast cancer associated with mammographic features in Singaporean Chinese women
###end article-title 150
###begin article-title 151
Dietary and lifestyle determinants of mammographic breast density: a longitudinal study in a Mediterranean population
###end article-title 151
###begin article-title 152
Life course breast cancer risk factors and adult breast density (United Kingdom)
###end article-title 152
###begin article-title 153
Life-course body size and perimenopausal mammographic parenchymal patterns in the MRC 1946 British birth cohort
###end article-title 153
###begin article-title 154
###xml 85 90 <span type="species:ncbi:9606">Women</span>
Menstrual and reproductive factors in relation to mammographic density: the Study of Women's Health Across the Nation (SWAN)
###end article-title 154
###begin article-title 155
Postmenopausal hormone therapy and change in mammographic density
###end article-title 155
###begin article-title 156
###xml 36 37 36 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
Cytochrome P450 CYP1B1 and catechol O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population
###end article-title 156
###begin article-title 157
Influence of estrogen receptor alpha and progesterone receptor polymorphisms on the effects of hormone therapy on mammographic density
###end article-title 157
###begin article-title 158
Polymorphisms in ER-alpha gene interact with estrogen receptor status in breast cancer survival
###end article-title 158
###begin article-title 159
Analysis of the ERalpha germline PvuII marker in breast cancer risk
###end article-title 159
###begin article-title 160
Genomic DNA analysis of the estrogen receptor gene in breast cancer
###end article-title 160
###begin article-title 161
###xml 32 37 <span type="species:ncbi:9606">human</span>
Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism
###end article-title 161
###begin article-title 162
Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility
###end article-title 162
###begin article-title 163
Genetic polymorphisms of the CYP19A1 gene and breast cancer survival
###end article-title 163
###begin article-title 164
Genetic polymorphisms in the estrogen receptor alpha gene and risk of breast cancer: Results from the Shanghai Breast Cancer Study
###end article-title 164
###begin article-title 165
###xml 145 150 <span type="species:ncbi:9606">women</span>
A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives
###end article-title 165
###begin article-title 166
The estrogen receptor alpha gene and breast cancer risk (The Netherlands)
###end article-title 166
###begin article-title 167
Estrogen receptor alpha polymorphisms and postmenopausal breast cancer risk
###end article-title 167
###begin article-title 168
Joint effects of the CYP1A1 MspI, ERalpha PvuII, and ERalpha XbaI polymorphisms on the risk of breast cancer: Results from a population-based case-control study in Shanghai, China
###end article-title 168
###begin article-title 169
Estrogen receptor alpha gene polymorphisms and breast cancer risk
###end article-title 169
###begin article-title 170
###xml 105 110 <span type="species:ncbi:9606">women</span>
Genetic determinants of bone mass do not relate with breast cancer risk in US white and African-American women
###end article-title 170
###begin article-title 171
###xml 77 82 <span type="species:ncbi:9606">women</span>
Estrogen receptor alpha haplotypes and breast cancer risk in older Caucasian women
###end article-title 171
###begin article-title 172
Oestrogen receptor alpha gene haplotype and postmenopausal breast cancer risk: a case control study
###end article-title 172
###begin article-title 173
ESR1 and EGF genetic variation in relation to breast cancer risk and survival
###end article-title 173
###begin article-title 174
Haplotype analyses of CYP19A1 gene variants and breast cancer risk: Results from the Shanghai Breast Cancer Study
###end article-title 174
###begin article-title 175
Mammographic breast density, dense area, and breast area differences by phase in the menstrual cycle
###end article-title 175
###begin article-title 176
Mammographic density changes during the menstrual cycle
###end article-title 176
###begin article-title 177
###xml 74 79 <span type="species:ncbi:9606">women</span>
Variation in mammographic breast density by time in menstrual cycle among women aged 40-49 years
###end article-title 177
###begin article-title 178
Differences in measured mammographic density in the menstrual cycle
###end article-title 178
###begin article-title 179
###xml 65 70 <span type="species:ncbi:9606">women</span>
###xml 108 113 <span type="species:ncbi:9606">Women</span>
Sex steroid hormone pathway genes and health-related measures in women of 4 races/ethnicities: the Study of Women's Health Across the Nation (SWAN)
###end article-title 179

